Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

A novel test trio to detect peptide biomarkers in saliva and blood for enhanced diagnosis and management of Alzheimer's Disease

Objective

FluiDx-AD aims to transform Alzheimer’s disease (AD) diagnosis and prepare the EU healthcare systems for the emergence of new AD therapies, with a 1st-in-class trio of In Vitro Diagnostics tests.
FluiDx-AD tests detect a unique and proprietary suite of biomarkers in simple bodily fluids (saliva, plasma/blood), towards widespread, patient-empowering, and all-inclusive AD diagnosis, at least as accurate as the costly and invasive procedures currently in place.
FluiDx-AD tests have the potential to shorten AD diagnosis by 7-15 years, by detecting biomarkers that mark the onset of AD years before the appearance of clinical symptoms. Earlier diagnosis means earlier access to preventive interventions, which are now more effective thanks to next-generation immunotherapies. The clinical use of these new drugs is not consensual though, because of the severe side-effects they inflict in some patients. FluiDx-AD tests offer a pioneering tool to stratify and monitor patients eligible for these drugs, towards reducing their associated risk and accelerating their regulatory clearance in the EU.
FluiDx-AD tests are thus devised to work complementarily and sequentially, covering the full AD diagnostic journey (from population-wide screenings to confirmatory diagnosis, and downstream patient stratification and monitoring), tackling key challenges of early AD diagnosis and AD prevention with new drugs, while also paving the way for the development of new therapies by streamlining patient selection and appraisal in clinical trials.
FluiDx-AD brings together a team of highly motivated, committed, and reputed entrepreneurs, clinicians, and scientists from biotechs, hospitals, academic centres, and patient organizations across the EU. Leveraging our unique blend of trans-disciplinary/-sectoral expertise and access to advanced technologies and infrastructures, we join forces to realize the vision of a new era of AD clinical management for the benefit of millions of patients globally.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-RIA - HORIZON Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-HLTH-2024-DISEASE-03-two-stage

See all projects funded under this call

Coordinator

OSLO UNIVERSITETSSYKEHUS HF
Net EU contribution
€ 1 158 125,00
Address
KIRKEVEIEN 166 TARNBYGGET
0450 Oslo
Norway
Region
Norge Oslo og Viken Oslo
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Participants (9)